1Reuter CW, Morgan MA, Bergmann L. Targeting the Ras signaling pathway:a rational, mechanism-based treatment for hematologic malignancies?Blood, 2000,96:1655-1669.
2Schaeffer HJ, Weber MJ. Mitogen-activated protein kinases:specific messages from ubiquitous messengers. Curr Opin Cell Biol,1999,19:2435-2444.
3Gibbs RA, Zahn TJ,Sebolt JS, et al. Non-peptidic prenyltransferase inhibitors:diverse structural classes and surprising anti-cancer mechanisms. Curr Med Chem,2001,8:1437-1465.
4Harousseau J L, Rapp M J, Robillard N, et al. Farnesyl transferase inhibitor R115777 indudes apoptosis of human myeloma cells. Leukemia,2002,16:1664-1667.
5Cusmai A, Piccoli C, Dammacco F, et al. Manumycin inhibitors famesyltransferase and induces apoptosis of drug-resistant interleukin 6-producing myeloma cells. Br J Haematol, 2002,118:157-165.
6Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias:a phaseⅠclinical-laboratory correlative trial.Blood,2001,97:3361-3369.
7Kurzrock R, Cortes J, Kantarjian H. Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome. Semin Hematol,2002,39 Suppl 3:20-24.
8Bernhard EJ, Mckenna WG, Hamilton AD, et al. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res, 1998,58:1754-1761.
9Peltenburg LT. Radiosensitivity of tumor cells: oncogenes and apoptosis.Q J Nucl Med,2000,44:355-364.
10Lobell RB, Liu D, Buser CA, et al. Preclinical and clinical pharmacodynamic assessment of L-778123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-Ⅰ. Mol Cancer Ther,2002,1:747-758.
2Vogel C L,Cobleigh M A,Tripathy D,et al.Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer[J].J Clin Oncol,2002,20(3):719-726.
3CrulM,KlerkGJ,Swart M,et al.Phase Ⅰ clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer[J].J Clin Oncol,2002,20(11):2726-2735.
4Johnston S R,Kelland L R.Farnesyl transferase inhibitors-a novel therapy for breast cancer[J].Endocr Relat Cancer,2001,8(3):227-235.
5Chiu V K,Bivona T,Hach A,et al.Ras signaling on the endoplasmic reticulum and the Golgi[J].Nat Cell Biol,2002,4(5):343-350.
6Feldkamp M M,Lau N,Roncari L,et al.Isotype-specific Ras.GTP-levels predict the efficacy of farnesyltransferase inhibitors against human astrocytomas regardless of Ras mutational status[J].Cancer Res,2001,61 (10):4425-4431.
7Johnston S R,Hickish T,Ellis P,et al.Phase Ⅱ study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor,R115777,in advanced breast cancer[J].J Clin Oncol,2003,21 (13):2492-2499.
8Wherlock M,Gampel A,Futter C,et al.Farnesyltransferase inhibitors disrupt EGF receptor traffic through modulation of the RhoB GTPase[J].J Cell Sci,2004,117 (15):3221-3231.
9Chen Z,Sun J,Pradines A,et al.Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice[J].J Biol Chem,2000,275(24):17974-17978.
10Chun K H,Lee H Y,Hassan K,et al.Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells[J].Cancer Res,2003,63(16):4796-4800.
